FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898813488> ?p ?o ?g. }

• W2898813488 endingPage "697" @default.
• W2898813488 startingPage "697" @default.
• W2898813488 abstract "Abstract Anti-CD19 chimeric antigen receptor (CAR) T cells have powerful activity against B-cell lymphoma, but improvement is clearly needed. Toxicity, including cytokine-release syndrome (CRS) and neurologic toxicity, occurs after anti-CD19 CAR T cell infusions. Most CAR T-cell toxicity is caused, either directly or indirectly, by cytokines or other proteins that are secreted from CAR T cells. The structure of a CAR is an extracellular antigen-recognition domain connected by hinge and transmembrane (TM) domains to intracellular T-cell signaling moieties. In vitro, T cells expressing CARs with hinge and TM domains from the CD8-alpha molecule released significantly lower levels of cytokines compared with T cells expressing CARs with hinge and TM domains from CD28; however, T cells expressing CARs with hinge and TM domains from CD8-alpha retained sufficient functional capability to eradicate tumors from mice (Alabanza et al. Molecular Therapy. 2017. 25(11) 2452). To reduce cytokine production with a goal of reducing clinical toxicity, we incorporated CD8-alpha hinge and TM domains into an anti-CD19 CAR. The CAR also had a human antigen-recognition domain, a CD28 costimulatory domain, and a CD3-zeta domain. This CAR was designated Hu19-CD828Z and was encoded by a lentiviral vector. Hu19-CD828Z was different from the FMC63-28Z CAR that we used in prior studies. FMC63-28Z had hinge and TM domains from CD28 along with a CD28 costimulatory domain, a CD3-zeta domain, and murine-derived antigen-recognition domains. Twenty patients with B-cell lymphoma were treated on a phase I dose-escalation clinical trial of Hu19-CD828Z T cells (Table). Patients received low-dose cyclophosphamide and fludarabine daily for 3 days on days -5 to -3. Two days later, on day 0, CAR T cells were infused. The overall response rate (ORR) after 1st treatments with Hu19-CD828Z T cells was 70%, and the complete response (CR) rate 55%; the 6-month event-free survival was 55%. The anti-lymphoma activity of Hu19-CD828Z T cells in the current trial was comparable to the anti-lymphoma activity of FMC63-28Z T cells in a similar prior trial that also enrolled patients with advanced B-cell lymphoma. In the prior trial, we observed a 73% ORR, a 55% CR rate, and a 6-month event-free survival of 64% in 22 patients treated with FMC63-28Z T cells (Kochenderfer et al. Journ. Clin. Oncology. 2017 35(16) 1803). In our previous clinical trial of FMC63-28Z T cells, the rate of Grade 3 or 4 neurologic toxicity among 22 patients treated was 55%. Strikingly, in our trial of Hu19-CD828Z T cells, the rate of Grade 3 or 4 neurologic toxicity was only 5% (1/20 patients). In addition, the rate of Grade 2 or greater neurologic toxicity with FMC63-28Z T cells was 77.3% while the rate of Grade 2 or greater neurologic toxicity with Hu19-CD828Z T cells was 15%. To explore the mechanism for the difference in neurologic toxicity in patients receiving FMC63-28Z T cells versus Hu19-CD828Z T cells, we assessed serum levels of 41 proteins in patients treated with these CAR T-cells. This comparison is valid because the same Luminex methodology was used for the serum protein analysis for both trials, and controls of known amounts of each protein were assayed to ensure that protein levels were comparable on the different trials. Lower levels of several serum proteins that might be important in CAR toxicity were found in patients treated with Hu19-CD828Z T cells versus patients treated with FMC63-28Z T cells: Granzyme A (P<0.001), Granzyme B (P<0.001), interferon gamma (P=0.011), interleukin (IL)-15 (P=0.007), IL-2 (P=0.0034), and macrophage inflammatory protein-1A (P<0.001). Median peak patient blood CAR+ cell levels were 44 cells/µL for Hu19-CD828Z and 46.5 cells/µL for FMC63-28Z (P=not significant). We hypothesize that lower levels of potentially neurotoxic proteins in patients receiving Hu19-CD828Z T cells versus FMC63-28Z T cells led to a lower frequency of neurologic toxicity in patients receiving Hu19-CD828Z T cells. The lower levels of immunologically active proteins found in the serum of patients receiving Hu19-CD828Z T cells compared with patients receiving FMC63-28Z T cells is consistent with our in vitro experiments showing lower cytokine production by T cells expressing CARs with CD8 hinge and TM domains versus CD28 hinge and TM domains. Altering CAR hinge and TM domains can affect CAR T-cell function and is a promising approach to improve the efficacy to toxicity ratio of CAR T-cells. Disclosures Rossi: KITE: Employment. Shen:Kite, a Gilead Company: Employment. Xue:Kite, a Gilead Company: Employment. Bot:KITE: Employment. Rosenberg:Kite, a Gilead Company: Research Funding. Kochenderfer:Kite a Gilead Company: Patents & Royalties: CAR technology, Research Funding; Celgene: Research Funding." @default.
• W2898813488 created "2018-11-09" @default.
• W2898813488 creator A5003258570 @default.
• W2898813488 creator A5011431831 @default.
• W2898813488 creator A5017546608 @default.
• W2898813488 creator A5035585356 @default.
• W2898813488 creator A5036697217 @default.
• W2898813488 creator A5037782727 @default.
• W2898813488 creator A5044366730 @default.
• W2898813488 creator A5046355832 @default.
• W2898813488 creator A5057158251 @default.
• W2898813488 creator A5064185471 @default.
• W2898813488 creator A5065897197 @default.
• W2898813488 creator A5066218992 @default.
• W2898813488 creator A5070180314 @default.
• W2898813488 creator A5072166479 @default.
• W2898813488 creator A5072304255 @default.
• W2898813488 creator A5073534731 @default.
• W2898813488 creator A5076289002 @default.
• W2898813488 creator A5089904138 @default.
• W2898813488 creator A5090875956 @default.
• W2898813488 date "2018-11-29" @default.
• W2898813488 modified "2023-09-27" @default.
• W2898813488 title "Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR" @default.
• W2898813488 doi "https://doi.org/10.1182/blood-2018-99-113731" @default.
• W2898813488 hasPublicationYear "2018" @default.
• W2898813488 type Work @default.
• W2898813488 sameAs 2898813488 @default.
• W2898813488 citedByCount "7" @default.
• W2898813488 countsByYear W28988134882019 @default.
• W2898813488 countsByYear W28988134882020 @default.
• W2898813488 countsByYear W28988134882021 @default.
• W2898813488 countsByYear W28988134882022 @default.
• W2898813488 crossrefType "journal-article" @default.
• W2898813488 hasAuthorship W2898813488A5003258570 @default.
• W2898813488 hasAuthorship W2898813488A5011431831 @default.
• W2898813488 hasAuthorship W2898813488A5017546608 @default.
• W2898813488 hasAuthorship W2898813488A5035585356 @default.
• W2898813488 hasAuthorship W2898813488A5036697217 @default.
• W2898813488 hasAuthorship W2898813488A5037782727 @default.
• W2898813488 hasAuthorship W2898813488A5044366730 @default.
• W2898813488 hasAuthorship W2898813488A5046355832 @default.
• W2898813488 hasAuthorship W2898813488A5057158251 @default.
• W2898813488 hasAuthorship W2898813488A5064185471 @default.
• W2898813488 hasAuthorship W2898813488A5065897197 @default.
• W2898813488 hasAuthorship W2898813488A5066218992 @default.
• W2898813488 hasAuthorship W2898813488A5070180314 @default.
• W2898813488 hasAuthorship W2898813488A5072166479 @default.
• W2898813488 hasAuthorship W2898813488A5072304255 @default.
• W2898813488 hasAuthorship W2898813488A5073534731 @default.
• W2898813488 hasAuthorship W2898813488A5076289002 @default.
• W2898813488 hasAuthorship W2898813488A5089904138 @default.
• W2898813488 hasAuthorship W2898813488A5090875956 @default.
• W2898813488 hasBestOaLocation W28988134881 @default.
• W2898813488 hasConcept C147483822 @default.
• W2898813488 hasConcept C148125776 @default.
• W2898813488 hasConcept C153911025 @default.
• W2898813488 hasConcept C167672396 @default.
• W2898813488 hasConcept C203014093 @default.
• W2898813488 hasConcept C2776090121 @default.
• W2898813488 hasConcept C2778690821 @default.
• W2898813488 hasConcept C2778957590 @default.
• W2898813488 hasConcept C3875195 @default.
• W2898813488 hasConcept C86803240 @default.
• W2898813488 hasConcept C8891405 @default.
• W2898813488 hasConceptScore W2898813488C147483822 @default.
• W2898813488 hasConceptScore W2898813488C148125776 @default.
• W2898813488 hasConceptScore W2898813488C153911025 @default.
• W2898813488 hasConceptScore W2898813488C167672396 @default.
• W2898813488 hasConceptScore W2898813488C203014093 @default.
• W2898813488 hasConceptScore W2898813488C2776090121 @default.
• W2898813488 hasConceptScore W2898813488C2778690821 @default.
• W2898813488 hasConceptScore W2898813488C2778957590 @default.
• W2898813488 hasConceptScore W2898813488C3875195 @default.
• W2898813488 hasConceptScore W2898813488C86803240 @default.
• W2898813488 hasConceptScore W2898813488C8891405 @default.
• W2898813488 hasIssue "Supplement 1" @default.
• W2898813488 hasLocation W28988134881 @default.
• W2898813488 hasOpenAccess W2898813488 @default.
• W2898813488 hasPrimaryLocation W28988134881 @default.
• W2898813488 hasRelatedWork W2076991609 @default.
• W2898813488 hasRelatedWork W2591646837 @default.
• W2898813488 hasRelatedWork W2953985020 @default.
• W2898813488 hasRelatedWork W3028561670 @default.
• W2898813488 hasRelatedWork W3159623678 @default.
• W2898813488 hasRelatedWork W4283333352 @default.
• W2898813488 hasRelatedWork W4309845615 @default.
• W2898813488 hasRelatedWork W4310106490 @default.
• W2898813488 hasRelatedWork W4318616170 @default.
• W2898813488 hasRelatedWork W620377004 @default.
• W2898813488 hasVolume "132" @default.
• W2898813488 isParatext "false" @default.
• W2898813488 isRetracted "false" @default.
• W2898813488 magId "2898813488" @default.
• W2898813488 workType "article" @default.